(NASDAQ: PRPH), a diversified biotech and genomics company, today announced that its Board of Directors has authorized. One share of PRPH stock can currently be purchased for approximately 11.39. The Company also continues to actively pursue strategic investments and acquisition opportunities for other companies, technologies and products. 08, 2021 (GLOBE NEWSWIRE) - ProPhase Labs, Inc. (“ProPhase Diagnostics”) to offer COVID-19 and other Respiratory Pathogen Panel (RPP) Molecular tests. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The Company is also developing ProPhase Diagnostics, Inc. A high-level overview of ProPhase Labs, Inc. This includes the development and marketing of dietary supplements under the TK Supplements ® brand. The Company is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near. (PRPH) was a big mover last session on higher-than-average trading volume. Step 1: Buy PRPH shares 1 day before the ex. Past performance is no guarantee of future results. ProPhase Labs (NASDAQ: PRPH) is a diversified medical science and technology company with deep experience with OTC consumer healthcare products and dietary supplements. (PRPH): Can Its 8 Jump Turn into More Strength Zacks - Tue Jul 26, 6:19AM CDT. Dividend capture strategy is based on PRPHs historical data. The company operates in two segments, Diagnostic Services and Consumer Products. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. ProPhase intends to grant the underwriters a 30-day option to purchase up to 15% of the shares sold to the public in the offering at the public offering price, to cover over-allotments, if any. The range between the high and low prices over the past day. About ProPhase Labs (NASDAQ:PRPH) Stock ProPhase Labs, Inc.
is acting as co-manager for the offering. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the Offering.
(NASDAQ: PRPH), a diversified medical science and technology company, announced today that it has commenced a proposed underwritten public offering of its common stock. The latest price target for ProPhase Labs (NASDAQ: PRPH) was reported by HC Wainwright & Co. 15, 2021 (GLOBE NEWSWIRE) - ProPhase Labs, Inc.